DIR Return Create A Forum - Home
---------------------------------------------------------
Camelot Fantasies
HTML https://castleknights.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: Stocks Universe
*****************************************************
#Post#: 48658--------------------------------------------------
OWCP
By: Clay Death Date: October 11, 2016, 6:19 pm
---------------------------------------------------------
HTML http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the
"Company"), an Israeli-based developer of cannabinoid-based
therapies targeting a variety of different medical conditions
and disorders, today announced it is starting the final phase
for testing the efficacy of its own developed topical crème
compound for the treatment of psoriasis and related skin
conditions.
(Logo:
HTML http://photos.prnewswire.com/prnh/20150311/734965-a
)
(Logo:
HTML http://photos.prnewswire.com/prnh/20150311/734965-b
)
The Company's recently completed Challenge Testing for the
topical crème, successfully demonstrated the product's
robustness against microbiological contamination, stability, and
provided a preliminary safety assessment. This next phase of
Safety testing protocol was designed to corroborate that the
cream is safe for application to the skin. This will be
demonstrated by giving a highly concentrated topical crème
formulation to healthy patients within a hospital controlled
environment. The safety phase will start upon receiving the
Institutional Review Board (IRB) approval by the national IRB
committee which is expected to be assembled in November 2016.
OWC is also preparing to initiate in parallel Efficacy Testing
using MatTek Corporation patented EpiDerm™ system, an in-vitro
testing technology for dermal toxicologists. This protocol will
seek to prove the effectiveness of the formulation in treating
psoriasis on human skin tissue. The tests will be conducted at
an approved international lab of Dead Sea & Arava Science Center
under the auspices of the Ben-Gurion University of the Negev
(
HTML http://www.adssc.org/
).
Dr. Yehuda Baruch, the Company's Director of Research and
Regulatory Affairs, commented on the announcement, "Psoriasis is
an affliction of the immune system resulting in sub-dermal
infection that can be painful and uncomfortable. Cannabis is
believed to provide relief from some infections and skin
conditions, and it is a central ingredient in our topical crème
formulation. Our preliminary studies indicate the formulation
does provide relief of these symptoms, and we are confident that
these studies will corroborate those results."
Ziv Turner, OWC's CEO, went on to say, "We are excited to begin
this last phase of testing so that we can finally make this
product available for all psoriasis sufferers. We hope to start
sales and marketing both in Israel the US in the second quarter
of 2017, and have already been in contact with a number of
representatives who have expressed interest in manufacturing and
distributing the crème in their state. Of course, we also
continue our work on multiple myeloma and other conditions, so I
am hopeful that this is just the first of many products that
will follow."
Psoriasis is an autoimmune disease that causes red, scaly
patches to appear on the skin, and can be associated with other
serious health conditions, including diabetes, heart disease and
depression. Skin cells in patients with psoriasis grow at an
abnormally fast rate, causing a buildup of lesions that tend to
burn and itch. While the real cause of psoriasis is not known,
genetics are believed to play a major role in its development.
According to the National Psoriasis Foundation, psoriasis
affects 7.5 million people in the United States.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned
Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC"
or the "Company") conducts medical research and clinical trials
to develop cannabis-based pharmaceuticals and treatments for
conditions including multiple myeloma, psoriasis, fibromyalgia,
PTSD, and migraines. OWC is also developing unique delivery
systems for the effective delivery and dosage of medical
cannabis. All OWC research is conducted at leading Israeli
hospitals and scientific institutions, and led by
internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical
trials evaluating the effectiveness of cannabinoids for the
treatment of various medical conditions, while its Consulting
Division is dedicated to helping governments and companies
navigate complex international cannabis regulatory frameworks.
For more information, visit:
HTML http://www.owcpharma.com/
#Post#: 49763--------------------------------------------------
Re: OWCP
By: Clay Death Date: October 29, 2016, 8:21 pm
---------------------------------------------------------
HTML http://www.cannabisfn.com/cfnvideo/?id=sLXXiKPI
#Post#: 49778--------------------------------------------------
Re: OWCP
By: Clay Death Date: October 30, 2016, 5:29 pm
---------------------------------------------------------
HTML https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-has-enough-catalysts-to-hold-onto-its-gains-and-more/117864/
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Has Enough
Catalysts To Hold Onto Its Gains And More
By Chris Sandburg / in Biotech & Pharma, Momentum Stocks,
Sector Watch, Stocks / on Thursday, 27 Oct 2016 09:25 PM /
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been on an
incredible run as late. The company kicked off the month trading
for around $0.015 share. Early this week, OWC went for $0.15
share – a 900% gain across the period. The last couple of
sessions has seen the company give back a portion of these
gains, and we think this might be a nice opportunity to prick up
an exposure on the pullback.
Here’s what we’re looking at.
First, and for those not familiar with the company, let’s kick
things off with a brief introduction. OWC is the parent company
of wholly owned subsidiary, One World Cannabis Ltd. The entity
reports through OWC, but operates under the One World sub. As a
quick note, this One World brand is mistakenly listed on a
number of the major financial sites as One Word – overlook the
error, it’s the same brand.
The company’s goal is to enter the cannabis pharmaceutical
space, through the application of the standard pharmaceutical
development framework (rigorous testing, application for
approval etc.) to various incarnations of the cannabis plant and
its active compounds.
Through a few collaboration agreements, all of which are rooted
in a primary collaboration with the leading Israeli medical
center and research hospital, Sheba, it is targeting three
initial indications: psoriasis, fibromyalgia and multiple
myeloma. There are a couple of secondary target indications
lower down the pipeline – PTSD and migraines – but for the
purposes of this discussion (i.e. what’s going to drive near
term value) we can overlook these for now.
So, what’s behind the recent gains?
Well, we’ve mentioned this on numerous occasions this week – the
cannabis sector is on fire. The upcoming legalization vote out
of California has had investors scrambling for an exposure to
the growth, and companies across the board are picking up
strength. This is the primary driver behind the action we’ve
seen this month, and it’s turned OWC in to a top momentum pick
as late.
We’re not subscribing to the hysteria, however. We’re looking
for companies that are likely to hold on to gains after the
excitement dies down. Whatever happens in California, a large
portion of the companies gaining strength right now are going to
crash (of course, this crash is going to be more severe if
Californian’s vote against the ballot). As such, we want
companies with near term catalysts that can help provide a floor
to the correction, and going forward, serve as a platform from
which to build post-hysteria momentum.
OWC’s three pronged pipeline meets these criteria.
The first catalyst on our watch list is the initiation of a
clinical program in the company’s psoriasis topical treatment.
In vitro studies are complete, and OWC expects to kick off a
healthy volunteer study at the above mentioned Sheba at some
point early November. With this sort of treatment, the path to
market is very short. As long as the company can prove the
medication safe, it can start commercialization in the US and
Israel concurrently. Safety is based on the just mentioned
trial, so managements expects sales to start rolling in as soon
as the second quarter of next year.
Looking at myeloma (which OWC bills as its most advanced
program) there’s not a whole lot of detail available as to
progress, but we know the following. First, pre-clinically, the
company demonstrated that some combinations of THC and CBD led
to the eradication of 100% of myeloma cells in 60% of tested
cultured cells within 24 to 48 hours of exposure to the
cannabinoid formulation.
In the latest 10Q, OWC stated it would kick off a clinical study
in first quarter 2016, but an update in May detailed the
completion of some mouse studies, and the following quote is
essentially all we’ve got to go on:
““We hope that the efficacy and safety will give us the comfort
we need to continue on to the human stage of testing.” Dr.
Yehuda Baruch, OWC’s Director of Research.
We are looking at the next update on this program before the
close of the year, and we expect some upside momentum if the
company can present a protocol and – in turn – a potential
pathway to the clinic.
Finally, we’re looking at progress in a sublingual tablet to
provide what we might refer to as bread and butter upside. It’s
not going to be a game changer, but the program should provide a
nice steady stream of positive press releases. In turn, it
should help to support the floor we discussed a little earlier.
#Post#: 49953--------------------------------------------------
Re: OWCP
By: Clay Death Date: November 3, 2016, 8:36 pm
---------------------------------------------------------
OWC Pharmaceutical Research Corp Signs Investment and Joint
Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical
Psoriasis Treatment in the European Union
HTML http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-signs-investment-and-joint-venture-with-michepro-holdings-ltd-599813021.html<br
/>
OWC Pharmaceutical Research Corp Signs Investment and Joint
Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical
Psoriasis Treatment in the European Union
NEWS PROVIDED BY
OWC Pharmaceutical Research Corp.
Nov 03, 2016, 08:21 ET
PETACH TIKVA, Israel, November 3, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the
"Company"), through its Israeli based fully owned subsidiary, a
developer of cannabinoid-based therapies targeting a variety of
different medical conditions and disorders, today announced it
has inked agreement for a combined JV & Private Placement of
$300,000 with Michepro Holding Ltd a private family investment
company organized under the laws of the state of Cyprus ("The
Investor\ partner ").
The Investor will be issued with 2,307,692 restricted shares of
the Company's common stock (a price of $0.13 per share) with
additional warrants to purchase 761,538 restricted shares at an
exercise price of $0.25 per share for a period of 24 months, and
additional warrants for 761,538 restricted shares at an exercise
price of $0.40 per share for a period of 36 months. In addition
to the investment, the parties will establish a joint venture,
75% to OWCP and 25% to Michepro Holding Ltd to promote, sell,
market and distribute the Company's potential products in
Europe, initially with the psoriasis treatment, to be followed
with company's other therapies as they become available."
Continue Reading
Cannabinoids-enriched innovative delivery systems by One World
Cannabis. A soluble tablets for sublingual use as a smoke-free
alternative, and a topical crème designated for skin diseases
starting with Psoriasis.
Cannabinoids-enriched innovative delivery systems by One World
Cannabis. A soluble tablets for sublingual use as a smoke-free
alternative, and a topical crème designated for skin diseases
starting with Psoriasis.
Cannabinoids-enriched innovative delivery systems by One World
Cannabis. A soluble tablets for sublingual use as a smoke-free
alternative, and a topical crème designated for skin diseases
starting with Psoriasis. (PRNewsFoto/OWC Pharmaceutical Research
Corp)OWCP Logo
The World Health Organization's 2016 Global Report on Psoriasis
states that psoriasis is a serious global problem affecting at
least 100 million individuals worldwide. The report indicates
the prevalence of psoriasis ranges from 0.09% in countries with
warmer climates to 11.43% in Norway, where a colder climate
prevails. The European market for psoriasis is estimated to be
15-20 Million patients.
Mr. Mordechai Bignitz, OWCP's Chairman and CEO, commented on
the announcement, "We are excited to partner with Michepro
Holding Ltd. The investment proceeds will be used to accelerate
development of several of OWCP's products and support
international marketing activities". Mr. Bignitz went on to say:
"the recent activity in OWC stock has given rise to numerous
investment proposals, but after reviewing the options we believe
that Michepro Holding Ltd represents the best opportunity for
the Company and our shareholders. Their EU business development
experience and marketing expertise, as well as their enthusiasm
about our future as a company are very encouraging, and it is
the perfect follow-up to the agreement with signed with MedMar
for the US."
Mr. Bignitz competed, "We believe the European market
represents a substantial opportunity. Medical cannabis is
already administrated in some countries in Europe, with several
markets indicating they are on the brink of approval. Our
initial focus will be the Netherlands, Czech Republic, Italy,
Germany and the UK."
Commenting on his investment, Mr. Michael Brath a Director of
Michepro Holding Ltd said, "OWC is the perfect match to our
investment strategy; they are pioneers in the field of medical
cannabis clinical research and we see incredible value in the
work they are doing which is exactly what has been missing from
thisMMJ market. We decided to invest and partner with them
because I believe that our resources across the EU will
significantly accelerate their ability to commercialize those
efforts throughout that market - initially with the psoriasis
treatment, and then with other therapies as they come online"
Psoriasis is an autoimmune disease that causes red, scaly
patches to appear on the skin, and can be associated with other
serious health conditions, including diabetes, heart disease and
depression. Skin cells in patients with psoriasis grow at an
abnormally fast rate, causing a buildup of lesions that tend to
burn and itch. While the real cause of psoriasis is not known,
genetics are believed to play a major role in its development.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned
Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC"
or the "Company") conducts medical research and clinical trials
to develop cannabis-based pharmaceuticals and treatments for
conditions including multiple myeloma, psoriasis, fibromyalgia,
PTSD, and migraines. OWC is also developing unique delivery
systems for the effective delivery and dosage of medical
cannabis. All OWC research is conducted at leading Israeli
hospitals and scientific institutions, and led by
internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical
trials evaluating the effectiveness of cannabinoids for the
treatment of various medical conditions, while its Consulting
Division is dedicated to helping governments and companies
navigate complex international cannabis regulatory frameworks.
For more information, visit:
HTML http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that
term is defined in Section 27A of the United States Securities
Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Statements in this press
release, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, filing
patent applications, product development, and business strategy.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated
with new projects and development stage companies. These
forward-looking statements are made as of the date of this news
release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein
and should also refer to the risk factors disclosure outlined in
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports
filed from time-to-time with the Securities and Exchange
Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Opportunity is Everywhere. Take Advantage by Opening an E*TRADE
Account.Advertisement
.
#Post#: 50068--------------------------------------------------
Re: OWCP
By: Clay Death Date: November 5, 2016, 9:30 pm
---------------------------------------------------------
HTML https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-consolidating-before-heading-higher/118094/
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Consolidating
Before Heading Higher
By Alex Carlson / in Biotech & Pharma, Momentum Stocks, Sector
Watch, Stocks / on Friday, 04 Nov 2016 02:55 AM / 0 Comment /
487 views
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been one of
the biggest winners for investors in the cannabis space. OWCP
was trading as low as $.0030 at the end of September before
turning into a microcap runner last month and hitting highs of
$.2150 on October 24. Now, OWCP has pulled back on profit taking
and looks to consolidate before resuming its push higher. In
looking at the news coming out of the company, we believe there
are a number of upcoming catalysts that will put OWCP back on
the trajectory of hitting new daily highs.
First up, a little background on the company. OWC Pharmaceutical
Research Corp., through its wholly-owned Israeli subsidiary, One
Word Cannabis Ltd., conducts medical research and clinical
trials to develop cannabis-based pharmaceuticals and treatments
for conditions including multiple myeloma, psoriasis,
fibromyalgia, PTSD, and migraines. OWCP is also developing
unique delivery systems for the effective delivery and dosage of
medical cannabis. The Company’s Research Division is focused on
pursuing clinical trials evaluating the effectiveness of
cannabinoids for the treatment of various medical conditions,
while its Consulting Division is dedicated to helping
governments and companies navigate complex international
cannabis regulatory frameworks.
The run-up in OWCP has allowed the company to raise money at
higher levels and avoid painful dilution. OWCP just signed an
investor agreement for a combined JV & Private Placement of
$300,000 with Michepro Holding Ltd, a private family investment
company. The Investor will be issued with 2,307,692 restricted
shares of the Company’s common stock (a price of $0.13 per
share) with additional warrants to purchase 761,538 restricted
shares at an exercise price of $0.25 per share for a period of
24 months, and additional warrants for 761,538 restricted shares
at an exercise price of $0.40 per share for a period of 36
months.
In addition to the investment, the parties will establish a
joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to
promote, sell, market and distribute the Company’s potential
products in Europe, initially with the psoriasis treatment, to
be followed with company’s other therapies as they become
available. Chairman and CEO Mordechai Bignitz said:
“ “We are excited to partner with Michepro Holding Ltd. The
investment proceeds will be used to accelerate development of
several of OWCP’s products and support international marketing
activities. We believe the European market represents a
substantial opportunity. Medical cannabis is already
administrated in some countries in Europe, with several markets
indicating they are on the brink of approval. Our initial focus
will be the Netherlands, Czech Republic, Italy, Germany and the
UK.”
Last month, OWCP completed the development of a proprietary,
cannabinoid-enriched sublingual tablet for the administration of
medical cannabis. The technology behind the Tablet is protected
and provides for the ingestion of virtually any dosage of
medical cannabis with a sublingual delivery mechanism, whereby
the compounds are absorbed directly into the patient’s blood
through oral epithelial tissue. The Tablet also enables
physicians to safely and accurately monitor the dosage and
treatment of each individual patient, something that is
essentially impossible to do for patients who administer
cannabis by smoking.
OWCP is working towards having the Tablet approved by the
Israeli Medicinal Cannabis Unit under the Ministry of Health
office for use within the country’s sanctioned medical cannabis
program, as well as talking with potential licensees of the
technology in the United States. Longer term, management expects
to establish clinical tests of the Tablet in protocols for
Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and
Fibromyalgia.
Going forward, we expect news coming from the company regarding
the final phase for testing the efficacy of its own developed
topical crème compound for the treatment of psoriasis and
related skin conditions. The Company’s recently completed
Challenge Testing for the topical crème, successfully
demonstrated the product’s robustness against microbiological
contamination, stability, and provided a preliminary safety
assessment. This next phase of Safety testing protocol was
designed to corroborate that the cream is safe for application
to the skin. This will be demonstrated by giving a highly
concentrated topical crème formulation to healthy patients
within a hospital controlled environment. The safety phase will
start upon receiving the Institutional Review Board (IRB)
approval by the national IRB committee which is expected to be
assembled in November 2016. Sales and marketing for the product
in both Israel and the U.S. is expected by the second quarter of
2017.
Currently trading with a market cap of $16.9 million, there are
135,305,474 outstanding shares and 86,515,750 shares in the
float according to the latest data from OTC Markets. While the
float is not as tight as it was in September, consider that the
30 day average daily volume has been almost 17 million shares.
As of October 15, there were almost 1 million shares short and
we think this number has picked up considerably. There’s still
plenty of shorts left to be squeezed and push OWCP higher. With
the news flow coming out of Israel, we believe this will be
happening sooner rather than later.
We will be updating our subscribers as soon as we know more. For
the latest updates on OWCP, sign up below!
Sign up for next microcap
#Post#: 50114--------------------------------------------------
Re: OWCP
By: Clay Death Date: November 8, 2016, 9:22 am
---------------------------------------------------------
JNi.media) Israeli Pharmaceutical company Teva appears to be
moving into the medical marijuana market, and a pending
acquisition could partially relieve the pain of its top drug,
Copaxone, going off patent.
Teva, according to a report by The Marker, has made an offer for
One World Cannabis (OWC) to purchase the rights to the company’s
patents. One World is developing treatments using the compound
in cannabis to treat chronic pain, multiple myeloma and other
conditions.
OWC recently reported a study by the Sheba Medical Center that
showed a 60% reduction of malignant multiple myeloma cells
within 24 hours of treatment using the cannabis plant’s active
ingredients. OWC is still in the early stages of developing a
drug, but the company expects the resultant treatment to be
licensed and available by prescription to those patients with
myeloma entitled to cannabis-based treatments.
OWC has hired Dr. Yehuda Baruch, former head of Israel’s
Ministry of Health’s Cannabis Unit as Director of Research.
Multiple myeloma is the second most common blood cancer after
non-Hodgkin lymphoma. It affects six out of every 100,00 people
and attacks the white blood cells, which produce antibodies that
fight infection. The malignant cancer cells collect in the bone
marrow where they disrupt the normal production of white blood
cells. The disease is diagnosed by a blood test and is
considered incurable but treatable with steroids, chemotherapy
or proteasome inhibitors. The survival rate is 45% for five
years.
#Post#: 50785--------------------------------------------------
Re: OWCP
By: Clay Death Date: November 28, 2016, 3:10 pm
---------------------------------------------------------
HTML http://www.otcmarkets.com/stock/OWCP/news/OWC-Pharmaceutical-Research-Corp-to-Submit-Psoriasis-Topical-Cream-IRB-Safety-Protocol-to-the-Israeli-National-IRB---quot-Helsinki-quot---Committee?id=144901&b=y
***8K***
Item 1.01. Entry Into A Material Definitive Agreement.
On November 27, 2016, OWC Pharmaceutical Research Corp. (the
"Registrant" or "OWCP") and its wholly-owned Israeli subsidiary,
One World Cannabis Ltd (OWC Ltd") entered into a license
agreement (the "License Agreement") with Emilia Cosmetics Ltd.,
a company organized under the laws of the State of Israel
("Emilia"), a world-leading company in the field of development,
production, manufacturing and packaging of health and beauty
products including for treatment of human skin disease. OWCP and
OWC Ltd are sometimes referred to collectively as "OWC."
Prior to entering into the License Agreement, the Parties
conducted a Development and Evaluation Program (as defined in
the License Agreement) for the development of a specific product
comprising Emilia's formulation with certain medical cannabis
extract provided by OWC Ltd for topical treatment of Psoriasis
("OWC's Product").
Pursuant to the License Agreement, a copy of which is attached
hereto as Exhibit 10.19, Emilia has granted a limited license to
OWC with respect to Emilia's Licensed Intellectual Property to
be developed and commercialized worldwide in the topical
treatment of Psoriasis in humans with OWC's Product and upon the
successful achievement of the trial, Emilia will grant OWC an
exclusive, worldwide, transferable, royalty-bearing license,
with the right to grant sublicenses, to use, sell and
commercially exploit the Emilia Intellectual Property (the
"License"). In consideration for the License, from and after the
first commercial sales of the Licensed Product, OWC shall pay to
Emilia a royalty at the rate of ten (10%) percent of net sales
during the period of time beginning upon the first commercial
sale and ending ten (10) years thereafter (the "Royalty Term").
In the event the sale of the Licensed Product during the Royalty
Term reaches the minimum sales targets mutually agreed by the
Parties as set forth in the License Agreement, the Royalty Term
will extend to an additional five (5) year term.
The foregoing descriptions of the License Agreement are
qualified in their entirety by reference to the full text of
thereof, a copy of which is attached hereto as Exhibit and which
is incorporated herein in its entirety by reference.
#Post#: 51478--------------------------------------------------
Re: OWCP
By: Divine Metamorphoses Date: December 11, 2016, 1:50 am
---------------------------------------------------------
Great board and thank you for all the information
Impressive
#Post#: 52274--------------------------------------------------
Re: OWCP
By: Clay Death Date: December 17, 2016, 8:42 am
---------------------------------------------------------
great to see you here lady D.
#Post#: 53264--------------------------------------------------
Re: OWCP
By: Clay Death Date: December 27, 2016, 9:19 am
---------------------------------------------------------
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) engages in the
research and development of Cannabis-based medical products.
OWCP provides medical products for the treatment of various
medical conditions and/or diseases, and provides consulting
services to companies and governmental agencies related to
international medical cannabis protocols and regulations. OWC
Pharmaceutical conducts medical research and clinical trials
through its wholly-owned Israeli subsidiary, One Word Cannabis
Ltd., in full compliance with all international regulatory
protocols, for the development of cannabis-based products and
treatments specifically designed for multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and of a unique
delivery system.
*****************************************************
DIR Next Page